Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A window of opportunity pilot study: TheraBionic P1 device for patients with resectable early-stage breast cancer in a neoadjuvant setting

    Cancer Categories
    • Breast
    Karmanos Trial ID
    • 2025-026
    NCT ID
    • NCT07218432
    Age Group
    • Adult
    Scope
    • Local
    PhaseClick for Clinical Trial Phase DefinitionQuestions, please contact us
    • N/A
    Principal Investigator
    • Lubina
      Arjyal, M.D.

      Gastroenterology, Oncology - Medical View Profile

    Objective:

    Primary Objective:

    • To descriptively summarize the pathological response of breast cancer to shortterm use of breast cancer-specific AM RF EMF therapy, delivered using the TheraBionic P1 device in patients with resectable early-stage breast cancer in the neoadjuvant setting

    Secondary Objectives:

    • To evaluate long term outcomes
    • To explore the effects of short-term delivery of breast cancer-specific AM RF EMF therapy on markers of breast tumor proliferation, apoptosis, and cell cycle arrest in pathological specimens
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions